Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1989;28(Suppl 1):3S–13S. doi: 10.1111/j.1365-2125.1989.tb03569.x

The pharmacology of xamoterol

A basis for modulation of the autonomic control of the heart

H M Snow
PMCID: PMC1379871  PMID: 2572252

Abstract

1 Xamoterol (Corwin, Carwin, Corwil, Xamtol, ICI 118,587) is a β-adrenoceptor partial agonist which is of benefit in the chronic treatment of heart failure (e.g. The German and Austrian Xamoterol Study Group, 1988). These results contrast with those obtained with other β-adrenoceptor drugs, prenalterol and pirbuterol which were unsuccessful on chronic dosing (Currie et al., 1984; Glover et al., 1985).

2 Unlike prenalterol and pirbuterol, xamoterol has no significant agonist activity at the β2-adrenoceptor and has shown no tachyphylaxis in animals or man.

3 The overall action of xamoterol is to modulate sympathetic control of the heart such that at rest and at low levels of exercise the heart receives inotropic support whilst during more severe exercise, heart rate is reduced. In patients with left ventricular dysfunction these effects lead to an improvement in the relation between filling pressure and cardiac output at all levels of activity such that a given cardiac output is achieved with a lower filling pressure. It is suggested that this alteration in the pattern of cardiac activity over a long period of time results in a beneficial adaptation of the myocardium and is a possible explanation of the observed clinical improvement.

Keywords: xamoterol, partial agonist, β1-adrenoceptor

Full text

PDF
3S

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barlow J. J., Main B. G., Snow H. M. Beta-adrenoceptor stimulant properties of amidoalkylamino-substituted 1-aryl-2-ethanols and 1-(aryloxy)-2-propanols. J Med Chem. 1981 Mar;24(3):315–322. doi: 10.1021/jm00135a015. [DOI] [PubMed] [Google Scholar]
  2. Black J. W., Leff P. Operational models of pharmacological agonism. Proc R Soc Lond B Biol Sci. 1983 Dec 22;220(1219):141–162. doi: 10.1098/rspb.1983.0093. [DOI] [PubMed] [Google Scholar]
  3. Bruce R. A., Hossack H. F., Kusumi F., Clarke L. J. Acute effects of oral propranolol on hemodynamic responses to upright exercise. Am J Cardiol. 1979 Jul;44(1):132–140. doi: 10.1016/0002-9149(79)90262-5. [DOI] [PubMed] [Google Scholar]
  4. Cook N., Richardson A., Barnett D. B. Comparison of the beta 1 selective affinity of prenalterol and corwin demonstrated by radioligand binding. Eur J Pharmacol. 1984 Mar 2;98(3-4):407–412. doi: 10.1016/0014-2999(84)90289-9. [DOI] [PubMed] [Google Scholar]
  5. Currie P. J., Kelly M. J., Middlebrook K., Federman J., Sainsbury E., Ashley J., Pitt A. Acute intravenous and sustained oral treatment with the beta1 agonist prenalterol in patients with chronic severe cardiac failure. Br Heart J. 1984 May;51(5):530–538. doi: 10.1136/hrt.51.5.530. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Detry J. M., Decoster P. M., Brasseur L. A. Hemodynamic effects of Corwin (ICI 118,587), a new cardioselective beta-adenoceptor partial agonist. Eur Heart J. 1983 Aug;4(8):584–591. doi: 10.1093/oxfordjournals.eurheartj.a061524. [DOI] [PubMed] [Google Scholar]
  7. Detry J. M., Decoster P. M., Buy J. J., Rousseau M. F., Brasseur L. A. Antianginal effects of corwin, a new beta-adrenoceptor partial agonist. Am J Cardiol. 1984 Feb 1;53(4):439–443. doi: 10.1016/0002-9149(84)90009-2. [DOI] [PubMed] [Google Scholar]
  8. Epstein S., Robinson B. F., Kahler R. L., Braunwald E. Effects of beta-adrenergic blockade on the cardiac response to maximal and submaximal exercise in man. J Clin Invest. 1965 Nov;44(11):1745–1753. doi: 10.1172/JCI105282. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Finegan R. E., Marlon A. M., Harrison D. C. Circulatory effects of practolol. Am J Cardiol. 1972 Mar;29(3):315–322. doi: 10.1016/0002-9149(72)90525-5. [DOI] [PubMed] [Google Scholar]
  10. Furnival C. M., Linden R. J., Snow H. M. The inotropic and chronotropic effects of catecholamines on the dog heart. J Physiol. 1971 Apr;214(1):15–28. doi: 10.1113/jphysiol.1971.sp009416. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Glover D. R., Wathen C. G., Murray R. G., Petch M. C., Muir A. L., Littler W. A. Are the clinical benefits of oral prenalterol in ischaemic heart failure due to beta blockade? A six month randomised double blind comparison with placebo. Br Heart J. 1985 Feb;53(2):208–215. doi: 10.1136/hrt.53.2.208. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Jennings G., Bobik A., Oddie C., Restall R. Cardioselectivity, kinetics, hemodynamics, and metabolic effects of xamoterol. Clin Pharmacol Ther. 1984 May;35(5):594–603. doi: 10.1038/clpt.1984.82. [DOI] [PubMed] [Google Scholar]
  13. Levy M. N., Zieske H. Autonomic control of cardiac pacemaker activity and atrioventricular transmission. J Appl Physiol. 1969 Oct;27(4):465–470. doi: 10.1152/jappl.1969.27.4.465. [DOI] [PubMed] [Google Scholar]
  14. Löfdahl C. G., Svedmyr N. Effects of xamoterol (ICI 118,587) in asthmatic patients. Br J Clin Pharmacol. 1984 Oct;18(4):597–601. doi: 10.1111/j.1365-2125.1984.tb02510.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Malta E., Mian M. A., Raper C. The in vitro pharmacology of xamoterol (ICI 118,587). Br J Pharmacol. 1985 May;85(1):179–187. doi: 10.1111/j.1476-5381.1985.tb08845.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Molajo A. O., Bennett D. H., Marlow H. F., Snow H. M., Bastain W. The effects and dose-response relationship of xamoterol in patients with ischaemic heart disease. Br J Clin Pharmacol. 1987 Sep;24(3):373–379. doi: 10.1111/j.1365-2125.1987.tb03183.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Nuttall A., Snow H. M. The cardiovascular effects of ICI 118,587: A beta 1-adrenoceptor partial agonist. Br J Pharmacol. 1982 Oct;77(2):381–388. doi: 10.1111/j.1476-5381.1982.tb09309.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Ohyagi A., Sasayama S., Nakamura Y., Lee J. D., Kihara Y., Kawai C. Effect of ICI 118,587 on left ventricular function during graded treadmill exercise in conscious dogs. Am J Cardiol. 1984 Nov 1;54(8):1108–1113. doi: 10.1016/s0002-9149(84)80154-x. [DOI] [PubMed] [Google Scholar]
  19. Parker J. O., West R. O., Di Giorgi S. Hemodynamic effects of propranolol in coronary heart disease. Am J Cardiol. 1968 Jan;21(1):11–19. doi: 10.1016/0002-9149(68)90007-6. [DOI] [PubMed] [Google Scholar]
  20. Reybrouck T., Amery A., Billiet L. Hemodynamic response to graded exercise after chronic beta-adrenergic blockade. J Appl Physiol Respir Environ Exerc Physiol. 1977 Feb;42(2):133–138. doi: 10.1152/jappl.1977.42.2.133. [DOI] [PubMed] [Google Scholar]
  21. Rousseau M. F., Brasseur L. A., Detry J. M. Haemodynamic and electrocardiographic effects of practolol during upright exercise in coronary heart disease. Cardiovasc Res. 1973 May;7(3):306–312. doi: 10.1093/cvr/7.3.306. [DOI] [PubMed] [Google Scholar]
  22. Sasayama S., Yokawa S., Akiyama M., Mikawa M., Sakai O. Cardiovascular effects of ICI 118,587, a new beta-adrenoceptor partial agonist in man. Jpn Circ J. 1986 Jul;50(7):636–643. doi: 10.1253/jcj.50.636. [DOI] [PubMed] [Google Scholar]
  23. Sato H., Inoue M., Matsuyama T., Ozaki H., Shimazu T., Takeda H., Ishida Y., Kamada T. Hemodynamic effects of the beta 1-adrenoceptor partial agonist xamoterol in relation to plasma norepinephrine levels during exercise in patients with left ventricular dysfunction. Circulation. 1987 Jan;75(1):213–220. doi: 10.1161/01.cir.75.1.213. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES